- This event has passed.
NCAN 2025 New Jersey NET Patient Conference
Date: Sunday September 21, 2025
Time: 8 AM to 5 PM EST
Location: Jack & Sheryl Morris Cancer Center
Address: 165 Somerset Street, New Brunswick, NJ
Join Us and:
Meet the Pioneers: Engage with leading experts who treat neuroendocrine cancer.
Explore Innovations: Speak with representatives from top labs, medical centers, and pharmaceutical companies in the NET field.
Connect & Share: Network with fellow patients and caregivers who truly understand your journey.
Don’t miss this incredible opportunity to gain insights, support, and hope.
Register for an NCAN patient conference and be part of a community dedicated to making a difference!
So Many NET Experts In One Place!
An impressive panel of speakers featuring some of the TOP NET specialists in the US.
- Howard Hochster, MD: Dr. Hochster is a nationally recognized medical oncologist and Associate Director for Clinical Research and Director of Gastrointestinal (GI) Oncology at Rutgers Cancer Institute. He is also Director of Oncology Research, RWJBarnabas Health, with a focus on advancing treatment through clinical trials. His research has contributed to the approval of multiple therapies for GI cancers, including neuroendocrine tumors. Dr. Hochster has authored over 150 peer-reviewed publications and leads national efforts in cancer research through the NCI and SWOG.
- Mary Maluccio, MD: Dr. Maluccio is a surgical oncologist and Director of the Rare Cancer Program and New Orleans Neuroendocrine Tumor Specialists (NOLANETS) at LSU Health Sciences Center. She specializes in complex surgical care for rare cancers, with a strong focus on both primary and metastatic neuroendocrine tumors. A leader in translational research, Dr. Maluccio serves as principal investigator on multiple clinical trials and is dedicated to improving diagnosis, treatment, and access to care for patients with rare and challenging cancers.
- Namrata Vijayvergia, MD: Dr. Vijayvergia is Assistant Chief of Gastrointestinal Medical Oncology and Medical Director of Medical Oncology at Fox Chase Cancer Center in Philadelphia. She specializes in the treatment of neuroendocrine tumors and other gastrointestinal cancers, with a strong focus on developing new therapies and identifying biomarkers to improve patient outcomes. Her research includes studying the molecular profile of neuroendocrine tumors to discover targeted treatments. Dr. Vijayvergia is nationally recognized for her contributions to clinical care and research, and actively serves on panels for the NCCN, NCI, and ECOG
- Miral Grandhi, MD: Dr. Grandhi is a surgical oncologist and Director of Hepatobiliary Surgery at Rutgers Cancer Institute. She specializes in gastrointestinal surgical oncology with a focus on liver, pancreas, bile duct, and gastric tumors, including neuroendocrine tumors. Trained at Johns Hopkins Hospital, she is skilled in advanced laparoscopic and robotic techniques. Dr. Grandhi is actively involved in clinical research and is committed to improving outcomes and quality of life for patients through multidisciplinary care and innovation.
- Miriam Eskander, MD, MPH: Dr. Eskander is a surgical oncologist at Rutgers Cancer Institute, specializing in gastrointestinal cancers including pancreatic, liver, and bile duct tumors. She has expertise in both open and robotic surgery. Her research focuses on cancer care delivery and improving access to clinical trials for vulnerable populations. She has over 60 peer-reviewed publications. She is a member of the GI disease site working group for the Society of Surgical Oncology and serves of the editorial board for the Annals of Surgical Oncology journal.
NCAN and Rutgers Cancer Institute collaborate to bring you a conference where you can build your NET knowledge.
Rutgers Cancer Institute offers access to innovative clinical trials for patients with endocrine and neuroendocrine tumors. These trials are part of their Endocrine and Neuroendocrine Tumor Program, which provides trials involving targeted therapies and immunotherapies.
Research HighlightsDr. Steven K. Libutti, William N. Hait Director of Rutgers Cancer Institute and Senior Vice President of Oncology Services, RWJBarnabas Health, is leading a major research initiative. His work focuses on:
- Investigating a novel immune checkpoint molecule called B7x
- Exploring how B7x may suppress the immune system’s ability to attack pancreatic NET
- Developing new immunotherapy strategies for NETs
This research is conducted in the Nancy Scott Amick Memorial Laboratory for Cancer Research, supported by philanthropic gifts.
Additional Innovations
Rutgers Cancer Institute is also exploring immunotherapy options specifically for carcinoid tumors and pancreatic NETs, addressing the limited treatment options currently available.
Clinical Program
Don’t Miss Out!
Join us for this transformative experience. Together, we can learn, grow, and advocate for better care and awareness.
REGISTER TODAY to secure your spot!
If you are a patient or caregiver, and want to attend an NCAN conference but are concerned about the cost, please email us. The Woltering NET Patient Scholarship is a donation-based program, and grants will be available as funding allows.
For information or to apply, email us at bob@netcancerawareness.org